#Japan #Tokyo #Gilead #Brexu-cel #MCL

Gilead Seeks Approval for Brexu-cel in Japan

Gilead Sciences, headquartered in Chiyoda, Tokyo, has recently filed for the domestic approval of brexucabtagene autoleucel, commonly known as brexu-cel, to target patients suffering from refractory or relapsed Mantle Cell Lymphoma (MCL) and B-cell Acute Lymphoblastic Leukemia (B-ALL). This move marks a significant step forward for innovative treatment options in Japan.

Brexu-cel is a CAR T-cell therapy that specifically targets CD19, a protein expressed on the surface of tumor cells. This groundbreaking treatment involves extracting T-cells from the patient’s own blood, genetically modifying them, and reintroducing them to mount an attack against cancerous cells. The hope is that this therapy will demonstrate anti-tumor efficacy against both MCL and B-ALL, potentially transforming the landscape of treatment options for these challenging conditions.

The application for approval is grounded in results from various clinical trials: an overseas Phase II trial (ZUMA-2) focused on patients with pre-treated MCL, a Phase I/II trial (ZUMA-3) concerning patients with B-ALL, and a domestic Phase II trial (JKART-1) on MCL and B-ALL patients. These studies have shown promising outcomes, reinforcing the need for advanced therapeutic alternatives in managing these recurrent cancers.

As for the diseases in question, MCL has a median overall survival of approximately 5-7 years and typically presents a challenging prognosis due to frequent relapses. Unfortunately, the current standard of care for MCL remains inadequate, with significant unmet needs for such patients. Similarly, B-ALL is notorious for its resistance to existing treatments and high rates of recurrence, highlighting a substantial gap in effective therapies.

Brexu-cel could fill this gap, offering a novel treatment direction for those battling MCL and B-ALL, both of which have historically hindered patients and their families.

About Gilead Sciences

Gilead Sciences aims to innovate healthcare solutions for a healthier world, having pursued medical advancements for nearly 40 years. The biopharmaceutical company has made significant strides in the prevention and treatment of life-threatening diseases such as HIV, viral hepatitis, and various forms of cancer. Operating from its headquarters in Foster City, California, Gilead serves patients in over 35 countries worldwide.

In Japan, brexu-cel has already been designated as a rare disease regenerative medicine product, gaining approval expected by January 2026 for both MCL and B-ALL treatments. Europe's and the United States’ prior approvals for these conditions underscore the growing recognition of CAR T-cell therapy's potential in overcoming therapeutic challenges.

As Gilead continues its mission to deliver transformative healthcare solutions, the anticipated approval of brexu-cel represents another step toward fulfilling their commitment to addressing unmet needs in oncology treatment and patient care. The company’s ongoing dedication to innovation reaffirms the quest for health equity and enhanced therapeutic choices on a global scale.